Enhanced Opsonisation of Rhesus D-positive Human Red Blood Cells by Recombinant Polymeric Immunoglobulin G Anti-G Antibodies

Overview

Journal Blood Transfus

Specialty Hematology

Date 2017 Jul 8

PMID 28686149

Authors

Dylana Diaz-Solano

Jaheli Fuenmayor

Ramon F Montano

Affiliations

Soon will be listed here.

Abstract

Background: Anti-RhD antibodies (anti-D) are important in the prophylaxis of haemolytic disease of the foetus and newborn (HDFN) due to RhD incompatibility. Current preparations of anti-D are sourced from hyperimmune human plasma, so its production carries a risk of disease and is dependent on donor availability. Despite the efforts to develop a monoclonal preparation with similar prophylactic properties to the plasma-derived anti-D, no such antibody is yet available. Here we studied the agglutinating, opsonic and haemolytic activities of two recombinant polymeric immunoglobulins (Ig) against the G antigen of the Rh complex.

Materials And Methods: Recombinant polymeric anti-G IgG1 (IgG1μtp) and IgG3 (IgG3μtp) were produced in vitro, purified by protein G-affinity chromatography, and analysed by gel electrophoresis. Their agglutinating, opsonic and haemolytic activities were evaluated using haemagglutination, erythrophagocytosis, and complement activation assays.

Results: The recombinant IgG1μtp and IgG3μtp anti-G antibodies ranged from 150,000 to 1,000,000 Da in molecular weight, indicating the formation of polymeric IgG. No complement activation or haemolytic activity was detected upon incubation of RhD-positive red-blood cells with the polymeric anti-G IgG. Both polymers were better opsonins than a prophylactic preparation of plasma-derived anti-D.

Discussion: The enhanced opsonic properties of the polymeric anti-G IgG1μtp and IgG3μtp could allow them to mediate the clearance of RhD-positive red blood cells from circulation more efficiently than natural or other synthetic prophylactic anti-D options. Their inability to induce complement-mediated haemolysis would be prophylactically convenient and is comparable in vitro to that of the available plasma-derived polyclonal anti-D preparations. The described properties suggest that polymeric antibodies like these (but with anti-D specificity) may be testable candidates for prophylaxis of HDFN caused by anti-D.

References

Montano R, Romano E . Human monoclonal anti-Rh antibodies produced by human-mouse heterohybridomas express the Gal alpha 1-3 Gal epitope. Hum Antibodies Hybridomas. 1994; 5(3-4):152-6. View

Fletcher A, Bryant J, Stavliotis M . Coordinator's report on the flow cytometric analysis of the Rh antibodies. Transfus Clin Biol. 1996; 3(6):407-13. DOI: 10.1016/s1246-7820(96)80054-1. View

Kumpel B, Wiener E, Urbaniak S, Bradley B . Human monoclonal anti-D antibodies. II. The relationship between IgG subclass, Gm allotype and Fc mediated function. Br J Haematol. 1989; 71(3):415-20. DOI: 10.1111/j.1365-2141.1989.tb04300.x. View

Armstrong-Fisher S, Carter M, Downing I, Fraser R, Inglis G, Allan E . Evaluation of a panel of human monoclonal antibodies to D and exploration of the synergistic effects of blending IgG1 and IgG3 antibodies on their in vitro biologic function. Transfusion. 1999; 39(9):1005-12. DOI: 10.1046/j.1537-2995.1999.39091005.x. View

Griffiths H, Kumpel B, Elson C, Hadley A . The functional activity of human monocytes passively sensitized with monoclonal anti-D suggests a novel role for Fc gamma RI in the immune destruction of blood cells. Immunology. 1994; 83(3):370-7. PMC: 1415029. View

Miescher S, De Jesus M, Moudry R, Fisch I, Vogel M, Kobr M . CHO expression of a novel human recombinant IgG1 anti-RhD antibody isolated by phage display. Br J Haematol. 2000; 111(1):157-66. DOI: 10.1046/j.1365-2141.2000.02322.x. View

Bowman J . Rh-immunoglobulin: Rh prophylaxis. Best Pract Res Clin Haematol. 2005; 19(1):27-34. DOI: 10.1016/j.beha.2005.03.003. View

Olovnikova N, Belkina E, Drize N, LEMENEVA L, Miterev G, Nikolaeva T . [Fast clearance of the rhesus-positive erythrocytes by monoclonal anti-rhesus antibodies--an insufficient condition for effective prophylaxis of rhesus-sensitization]. Biull Eksp Biol Med. 2000; 129(1):77-81. View

Wittig O, Alonso J, Romano E, Montano R . [A and B blood group-specific monoclonal antibodies. Production and evaluation as ABO-blood typing reagents]. Invest Clin. 2007; 47(3):253-64. View

10.

Anstee D, Tanner M . Biochemical aspects of the blood group Rh (rhesus) antigens. Baillieres Clin Haematol. 1993; 6(2):401-22. DOI: 10.1016/s0950-3536(05)80152-0. View

11.

Jones J, Scott M, Voak D . Monoclonal anti-D specificity and Rh D structure: criteria for selection of monoclonal anti-D reagents for routine typing of patients and donors. Transfus Med. 1995; 5(3):171-84. DOI: 10.1111/j.1365-3148.1995.tb00225.x. View

12.

Chauhan A, Bhattacharyya M, Turakhia N, Daftary G . Efficacy and safety of monoclonal anti-D immunoglobulin in comparison with polyclonal anti-D immunoglobulin in prevention of rho isoimmunization. J Assoc Physicians India. 2003; 50:1341-2. View

13.

Gebran S, Romano E, Pons H, Cariani L, Soyano A . A modified colorimetric method for the measurement of phagocytosis and antibody-dependent cell cytotoxicity using 2,7-diaminofluorene. J Immunol Methods. 1992; 151(1-2):255-60. DOI: 10.1016/0022-1759(92)90125-d. View

14.

Miescher S, Spycher M, Amstutz H, de Haas M, Kleijer M, Kalus U . A single recombinant anti-RhD IgG prevents RhD immunization: association of RhD-positive red blood cell clearance rate with polymorphisms in the FcgammaRIIA and FcgammaIIIA genes. Blood. 2004; 103(11):4028-35. DOI: 10.1182/blood-2003-11-3929. View

15.

Beliard R . Monoclonal anti-D antibodies to prevent alloimmunization: lessons from clinical trials. Transfus Clin Biol. 2006; 13(1-2):58-64. DOI: 10.1016/j.tracli.2006.03.013. View

16.

Kumpel B . Efficacy of RhD monoclonal antibodies in clinical trials as replacement therapy for prophylactic anti-D immunoglobulin: more questions than answers. Vox Sang. 2007; 93(2):99-111. DOI: 10.1111/j.1423-0410.2007.00945.x. View

17.

Ironside J . Variant Creutzfeldt-Jakob disease: an update. Folia Neuropathol. 2012; 50(1):50-6. View

18.

Hidalgo C, Romano E, Linares J, Suarez G . Complement fixation by Rh blood group antibodies. Transfusion. 1979; 19(3):250-4. DOI: 10.1046/j.1537-2995.1979.19379204205.x. View

19.

Seitz R, Heiden M . Quality and Safety in Blood Supply in 2010. Transfus Med Hemother. 2010; 37(3):112-117. PMC: 2889628. DOI: 10.1159/000314497. View

20.

Brinc D, Lazarus A . Mechanisms of anti-D action in the prevention of hemolytic disease of the fetus and newborn. Hematology Am Soc Hematol Educ Program. 2009; :185-91. DOI: 10.1182/asheducation-2009.1.185. View